Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEPirfenidone-d5Cat.No.:HY-B0673SCASNo.:1020719-62-3Synonyms:AMR69-d5分?式:C??H?D?NO分?量:190.25作?靶點(diǎn):TGF-beta/Smad;CCR作?通路:StemCell/Wnt;TGF-beta/Smad;GPCR/GProtein;Immunology/Inflammation儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(525.62mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM5.2562mL26.2812mL52.5624mL5mM1.0512mL5.2562mL10.5125mL10mM0.5256mL2.6281mL5.2562mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥5.95mg/mL(31.27mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥6.25mg/mL(32.85mM);Clearsolution3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥6.25mg/mL(32.85mM);ClearsolutionBIOLOGICALACTIVITY?物活性Pirfenidoned5(AMR69d5)Pirfenidone的氘代物。Pirfenidone?種抗纖維化劑，可減弱纖維細(xì)胞中CCL2和CCL12的產(chǎn)?。Pirfenidone具有抑制細(xì)胞?長(zhǎng)的作?，并能降低?膠質(zhì)瘤細(xì)胞系中的TGF-β2蛋??平。Pirfenidone還具有抗炎活性。IC50&TargetTGF-β2[1][2]CCL2andCCL12[3]REFERENCES[1].BurghardtI,etal.PirfenidoneinhibitsTGF-betaexpressioninmalignantgliomacells.BiochemBiophysResCommun.2007Mar9;354(2):542-7.[2].NakazatoH,etal.Anovelanti-fibroticagentpirfenidonesuppressestumornecrosisfactor-alphaatthetranslationallevel.EurJPharmacol.2002Jun20;446(1-3):177-85.[3].InomataM,etal.Pirfenidoneinhibitsfibrocyteaccumulationinthelungsinbleomycin-inducedmurinepulmonaryfibrosis.RespirRes.2014Feb8;15:16.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:4